Head-to-head · WeighScore
Breeze Meds vs Maves
The verdict
Breeze Meds takes it — 72.4/100 to 71.8/100, but only just.
Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake. Maves is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Breeze Meds | Maves |
|---|---|---|
| WeighScore | 72.4/100 | 71.8/100 |
| Grade | C | C |
| Scorecard rank | #55 | #89 |
| Semaglutide | From $199/mo | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | From $299/mo first month, $399/mo thereafter | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #55 · C
Strengths
- Nothing charged until a provider approves you, and the consult is free if you go ahead
- One inclusive price covering consult, medication, supplies, shipping and support
- LegitScript certified, all 50 states, cancel or change plan at any time
- NAD+ injections offered alongside the GLP-1 line
Where it loses points
- The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
- Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
- An $80 consultation fee applies if you are approved and then decline
- Injection only, compounded only, with no published lab programme
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.